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Abstract
Background: In order to improve malaria control, and under the aegis of WHO recommendations, many efforts are being
devoted to developing new tools for identifying geographic areas with high risk of parasite transmission. Evaluation of the
human antibody response to arthropod salivary proteins could be an epidemiological indicator of exposure to vector bites,
and therefore to risk of pathogen transmission. In the case of malaria, which is transmitted only by anopheline mosquitoes,
maximal specificity could be achieved through identification of immunogenic proteins specific to the Anopheles genus. The
objective of the present study was to determine whether the IgG response to the Anopheles gambiae gSG6 protein, from its
recombinant form to derived synthetic peptides, could be an immunological marker of exposure specific to Anopheles
gambiae bites.
Methodology/Principal Findings: Specific IgG antibodies to recombinant gSG6 protein were observed in children living in a
Senegalese area exposed to malaria. With the objective of optimizing Anopheles specificity and reproducibility, we designed
five gSG6-based peptide sequences using a bioinformatic approach, taking into consideration i) their potential antigenic
properties and ii) the absence of cross-reactivity with protein sequences of other arthropods/organisms. The specific anti-
peptide IgG antibody response was evaluated in exposed children. The five gSG6 peptides showed differing antigenic
properties, with gSG6-P1 and gSG6-P2 exhibiting the highest antigenicity. However, a significant increase in the specific IgG
response during the rainy season and a positive association between the IgG level and the level of exposure to Anopheles
gambiae bites was significant only for gSG6-P1.
Conclusions/Significance: This step-by-step approach suggests that gSG6-P1 could be an optimal candidate marker for
evaluating exposure to Anopheles gambiae bites. This marker could be employed as a geographic indicator, like remote
sensing techniques, for mapping the risk of malaria. It could also represent a direct criterion of efficacy in evaluation of
vector control strategies.
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Introduction
The threat from vector-borne diseases, considered to be major
public health problems in developing countries, is prompting
research and health community in developing new tools for
diseases control. Malaria is by far the most severe of these diseases.
It is transmitted by the Anopheles mosquitoes and is responsible each
year for at least 400 million acute cases globally, resulting in more
than one and a half million deaths [1]. The vast majority of
malaria deaths occur in sub-Saharan Africa and are caused by
Plasmodium falciparum, the most severe and life-threatening form of
the disease. In these areas the Anopheles gambiae complex is the
major vector. With a goal toward improving malaria control, the
‘‘Roll Back Malaria’’ partnership has recommended developing new
diagnostic tool, especially for identifying geographic areas with
high risk of transmission [1]. The evaluation of exposure to
malaria risk is currently based on entomological methods (traps,
household/indoor spraying, human-landing catches, etc.) but
such methods are mainly applicable at the population level and
do not enable evaluation of the heterogeneity of individual
exposure. Trapping methods using adult volunteers can estimate
individual exposure, but may be limited due to ethical constraints
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2472and limitations in terms of extrapolation to the incidence in
children [2].
Plasmodium parasites are injected together with saliva during
blood-feeding by an infected Anopheles female. Salivary proteins
play a dual role in facilitating mosquito blood feeding; their
pharmacological properties permit to counteract human defenses
triggered by dermis disruption (inflammatory and hemostasis) and
their immunological properties modulate the immune response of
the human host [3,4]. In addition, some salivary proteins are
immunogenic and can initiate a specific antibody (Ab) response
[5]. Linked to this interesting property, previous studies have
shown that the anti-saliva Ab response could be a potential marker
of exposure to vector-borne diseases in individuals exposed to bites
of arthropod vectors, such as ticks [6], phlebotomies [7], Triatoma
[8], Glossina [9] and also Aedes mosquitoes [10]. As concerns
Anopheles spp. and malaria transmission, early epidemiological
studies have shown that individuals living in malaria endemic
areas, i.e. exposed to Anopheles bites, develop a specific anti-saliva
Ab response [11,12]. In Senegal, our group has indeed
demonstrated that the IgG response to whole saliva extracts
(WSE) of An. gambiae represents a marker of exposure to An. gambiae
bites. In addition, high anti-saliva IgG levels appeared to be a
predictive indicator of malaria morbidity [11].
Some families of salivary proteins are widely distributed in
bloodsucking Diptera [13]. Taking this into account, the evaluation
of Anopheles exposure based on the immunogenicity of WSE could
be skewed and/or overestimated by possible cross-reactivity
between common epitopes on immunogenic salivary proteins
between mosquito species. An alternative for optimizing the
specificity of this immuno-epidemiological test would thus be to
identify Anopheles genus-specific proteins [14].
In the last decade, biochemical properties and the role played by
saliva and salivary glands of arthropods in the permissiveness of
transmission of pathogens has become a new research pathway for
diseasevectors [15,16].Related to the identification of the arthropod
genome, these studies were performed by high throughput
transcriptome and proteome analyses based on salivary gland cDNA
libraries [17]. In An. gambiae, a catalogue including 71 secreted
salivary proteins has recently been described [18]. Among these
proteins, the so-called Salivary Gland proteins (SG1-8) have been
reported to be Anopheles spp.-specific and may represent potential
candidate for elaborating genus-specific markers of exposure [19].
Furthermore, among these specific proteins, recent data
indicated that the gSG6 protein could be immunogenic in
individuals exposed to Anopheles. Indeed, via an immunoblotting
approach, a band with molecular weight corresponding to the
gSG6 protein (11–13 kDa) was identified as antigenic in
individuals briefly exposed to Anopheles bites [20]. In addition, in
Senegalese children living in an endemic area for malaria, the
gSG6 protein was recently confirmed as being antigenic by a 2D
approach coupled with mass spectrometry (Cornelie, unpublished
data). Above these 2 criteria, the gSG6 protein would seem to be a
relevant candidate for validating its potential as an immunological
marker specific to An. gambiae bites.
The objective of the present study was to determine whether the
IgG Ab response to the An. gambiae gSG6 antigen and derived
peptides is an immuno-epidemiological marker of exposure
specific to An. gambiae bites in children living in an endemic area
for malaria. Using a step-by-step approach, we investigated i) the
antigenicity of gSG6 expressed in recombinant form, ii) the
Anopheles-specificity and the antigenic potential of gSG6 peptides
designed using a bioinformatic approach, and iii) anti-gSG6
peptides IgG levels in exposed children according to An. gambiae
exposure as estimated by entomological methods.
Materials and Methods
Study population
The present study was conducted in Niakhar, a rural district of
central Senegal. This area is characterized by a dry savannah with
a rainy season from July to October (approximately 400 mm of
rainfall recorded). This area is typical of the Sahel and Sub-Sahel
regions of Africa, where the occurrence of malaria is unstable, with
a season of P. falciparum transmission mainly from September to
November [21,22]
Sera were available from a clinical trial on seasonal intermittent
preventive treatment for prevention of malaria performed in 2002 in
childrenaged6weeksto5years[22].Serafromasubsampleofthese
children were available at the peak (September) and at the end
(December) of the rainy season, as previously described [11]; 241
children were screened in September 2002 and, among them, 175
children were screened in both September and December 2002.
Both the trial on anti-malaria treatment and the present study
followed ethical principles according to the Edinburgh revision of
the Helsinki Declaration, and were approved by the ethical
committees of the Ministry of Health of Senegal (August 2002 and
May 2003, respectively) and of the IRD (Institute of Research for
the Development) (January 2004). The anti-malaria trial was
approved by the ethical committee of the London School of
Hygiene and Tropical Medicine in June 2002. Written informed
consent was obtained from the study population.
Entomological data
Entomological data were collected each month between Septem-
ber and December 2002 in 11 villages in the Niakhar area using
capture by light traps (CDC miniature light trap). Analysis of
entomological data led to defining 3 groups of individuals classified
by their exposure level to Anopheles gambiae bites (low, medium and
high exposure levels) as previously described [11].
Recombinant protein gSG6
An. gambiae gSG6 was expressed as recombinant protein in the
yeast Pichia pastoris (Arca ` B., unpublished data). cDNA coding for
mature gSG6 polypeptide was amplified by RT-PCR using gene-
specific oligonucleotide primers. Amplified fragments were
directionally cloned in the pPICZa vector (Invitrogen, Carlsbad,
CA) between sequences coding for the signal peptide of the
Saccharomyces cerevisiae a factor at the N-terminus and those coding
for the c-myc and polyhistidine tags at the C-terminus. Protein
expression was induced by addition of methanol (0.5%) to the
medium. After 24–48 hours, supernatants were collected by
centrifugation and the proteins were purified by Ni-NTA affinity
chromatography according to the manufacturer’s instructions
(Quiagen, Ontario, Canada). Affinity-purified fractions were
employed for the determination of IgG levels by ELISA.
Peptide design of gSG6 salivary protein
We investigated the design of potential immunogenic peptides
of the gSG6 protein using bio-informatic tools. The strategy was i)
to identify potential immunogenic epitopes predicted by algo-
rithms; and ii) to research the specificity of An. gambiae gSG6
peptide sequence compared to the genome/ Expressed Sequence
Tag (EST) libraries of other organisms.
This analysis was based on the amino acid sequence of mature
An. gambiae gSG6 (‘‘UniProtKB/TrEMBL:Q9BIH5’’ and
‘‘gi:13537666’’, [23]).
The identification of putative linear B-cell epitopes of An.
gambiae gSG6 was performed by computerized predictions of
antigenicity based on physico-chemical properties of the amino-
Biomarker An.gambiae Exposure
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FIMM database [25]. We also identified the MHC class 2 binding
regions using the ProPred-2 online service [26].
Sequence alignments were done with the Tblastn program in
Vectorbase database [27] which enabled comparing a sequence of
gSG6 peptides with known genomes or EST libraries of Aedes
aegypti, Ixodes scapularis, Culex pipiens, Pediculus humanus, Glossina
morsitans, Rhodnius prolixus, Lutzomia longipalpis and Phlebotomus
papatasi. Concomitantly, we investigated sequence alignments with
the Blast program to compare the gSG6 peptides sequence with all
non-redundant GenBank CDS database [28].
Peptides were synthesized and purified (.80%) with Genosys
(Sigma-Genosys, Cambridge, UK) with an added N-terminal
biotin. All peptides were shipped lyophilized and they were
resuspended in 0.22 mm filtered milliQ water and stored in
aliquots at 280uC.
Evaluation of human IgG Ab levels ELISA
ELISA was carried out using salivary antigens (gSG6 recom-
binant protein or biotinylated gSG6 peptides) and sera were tested
for IgG antibodies. Maxisorp plates (Nunc, Roskilde, Denmark)
were coated with recombinant protein (5 mg/mL) or gSG6
peptides (20 mg/mL for gSG6-P1, gSG6-P5 and 30 mg/mL for
gSG6-P2, gSG6-P3, gSG6-P4) in carbonate/bicarbonate buffer.
Individual sera were incubated in PBS-Tween 1% (1:10 for
assessment on recombinant protein, gSG6-P2 (subsample n,30)
and gSG6-P3, and 1:20 for assessment on gSG6-P1, gSG6-P2
(large sample n=241), gSG6-P4 and gSG6-P5). Anti-gSG6
peptides IgG detection was performed using an HRP goat anti-
human IgG Ab (1:25000, Nordic Immunology, Tilburg, Nether-
lands) and anti-recombinant protein IgG detection was performed
using a mouse biotinylated mAb (1:1000, BD Pharmingen, San
Diego, CA). Peroxidase-conjugated streptavidin (1:1000, Amer-
sham, Les Ulis, France) was added only for assay using
biotinylated secondary antibodies. Colorimetric development was
carried out using ABTS (2,29-azino-bis (3-ethylbenzthiazoline 6-
sulfonic acid) diammonium; Sigma, St Louis, MO) in 50 mM
citrate buffer (pH 4) containing 0.003% H2O2. Absorbance/
Optical Density (OD) was measured at 405 nm. In addition, the
absence of significant Ab detection was verified in wells without
antigen (ODn). Individual results were expressed as DOD value
calculated according to the formula DOD=ODx-ODn, where
ODx represented the individual OD value in antigen wells.
Statistical analysis
All data were analyzed with GraphPad Prism softwareH (San
Diego,CA, USA). After verifying that values did not assume
Gaussian distribution, the non-parametric Mann-Whitney U-test
was used for comparison of Ab levels between two independent
groups and the non-parametric Kruskal-Wallis test was used for
comparison between more than two groups. The Wilcoxon
matched pair test was used to compare paired sera between
September and December. All differences were considered
significant at P,0.05.
Results
Immunogenicity of gSG6 recombinant protein
The IgG response to recombinant gSG6 protein was evaluated
in a small sample of children living in the studied area. The
children (n=16) chosen for this initial test were selected for their
high level of IgG Ab specific to whole An. gambiae saliva
(0.532,ODWSE,1.499, [11]).
The level of IgG Ab to gSG6 (0.01,DOD,1.959) classified
according to the intensity of the DOD value is presented in
Figure 1. A high anti-gSG6 IgG response was observed in half of
the children. Interestingly, important variations in the anti-gSG6
IgG level were observed between exposed individuals ranging
from a low (Ind. 1–8) or intermediate (Ind. 9) to a high intensity of
the Ab level (Ind. 10–15).
Peptide design
The second step was to design gSG6-based peptides with the
objective of optimizing and increasing Anopheles specificity and
reproducibility of the assay, and overcoming limits in production
of the recombinant protein and possible batch-to-batch variations.
The identification of potential immunogenic epitopes of the gSG6
protein was done with bioinformatic tools. We employed several
algorithms for prediction of potential immunogenic sites (putative
linear B-cell epitopes and MHC class 2 binding regions). The
crossing of the immunogenic predicted epitopes led us to define 5
gSG6 peptides (gSG6-P1 to gSG6-P5) of 20 to 27 amino acid
residues in length, overlapping by at least 3 residues and spanning
the entire sequence of the mature gSG6 protein. Both predictive
methods for putative linear B-cell epitopes (FIMM and BcePred)
assigned the highest potential immunogenicity to gSG6-P1. This
peptide was followed in the predicted immunogenicity scale by
gSG6-P2 (according to BcePred) or by gSG6-P3 and gSG6-P4
(according to FIMM). Peptide sequences are shown in Figure 2.
In order to try to maximize Anopheles specificity and to avoid
potential immune cross-reactivity (with proteins from other vector
species as well as from pathogens or other organisms), we also
searched for similarities using the Blast family programs, including
both the genome/EST libraries of other vector arthropods
available in Vectorbase and of pathogens/organisms in non-
redundant GenBank CDS databases. No relevant similarity was
found with proteins of other bloodsucking arthropods, as indicated
by the low scores that were obtained (few amino acids
consecutively matched and high rate of e-value, i.e. e.0.13).
Indeed, the longest perfect match was six amino acids between a
putative protein from Pediculus humanus and gSG6-P2 and gSG6-P3
peptides (e=0.56). In the case of gSG6-P1, the best match was
four amino acids in length with Culex pipiens quinquefasciatus salivary
adenosine deaminase (e=0.95). Moreover, no relevant similarity
Figure 1. IgG antibody response specific to gSG6 recombinant
protein. The IgG antibody level was evaluated in children (n=16)
living in an endemic area for malaria. Individual DOD results (DOD as
described in the ‘‘Materials and Methods’’ section) at the peak of the
season of Anopheles exposure (September) are reported. Samples are
ordered according to the intensity of the individual DOD value.
doi:10.1371/journal.pone.0002472.g001
Biomarker An.gambiae Exposure
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highest hits of gSG6-P1 were with the cyanobacterium Microcystis
aeruginosa (three amino acids, e=2.6) and with Ostreococcus OsV5
virus (four amino acids, e=15).
This analysis confirmed the bona fide high specificity of the 5
selected gSG6 peptides for the Anopheles species.
Immunogenicity of gSG6 peptides
The following step was carried out to evaluate the IgG Ab
response to the five gSG6 peptides by ELISA in a randomly selected
subsample ofchildren(n,30) living inthestudiedarea (Figure 3).All
peptides were antigenic, but the intensity of the IgG level was clearly
peptide-dependent; weak antigenicity was observed for gSG6-P3,
gSG6-P4 and gSG6-P5, whereas gSG6-P1 and gSG6-P2 appeared
highly antigenic in this subsample of children.
IgG response to gSG6 peptides according to exposure to
An. gambiae bites
Entomological data led to defining 3 groups of individuals
classified by their exposure level (low:1.2961.11; medi-
um:16.7563.18; high:31.0863.47 bites/human/night,
mean6SD) as previously described [11]. Therefore, for each
gSG6 peptide, we first compared the specific IgG level according
to their exposure group, within the same randomly selected
subsample of children (data not shown). A positive trend between
the specific IgG level and the intensity of exposure was found for
gSG6-P1 and for gSG6-P2 in this subsample and this association
was only significant for gSG6-P1 (P,0.05). In contrast, gSG6-P3,
gSG6-P4 and gSG6-P5 were weakly immunogenic, as also
previously mentioned (Figure 3), In addition, the intensity of
IgG Ab levels to these 3 peptides was similar whatever the 3
groups of exposure level (data not shown). For all these reasons,
the next stage consisted of validating only gSG6-P1 and gSG6-P2
peptides as markers of exposure in a larger immuno-epidemio-
logical analysis according to entomological data. The IgG level
specific to gSG6-P1 and gSG6-P2 was then evaluated in children
(n=241) according to their exposure group at the peak of the
season of An. gambiae exposure (September), as defined by
entomological data (Figure 4). The IgG response showed
significant differences according to exposure groups for both
peptides (P,0.0001 for gSG6-P1 and P=0.0195 for gSG6-P2,
respectively, Kruskal-Wallis test). The anti-gSG6-P1 IgG level was
similar in children in the low and medium exposure groups,
whereas it was significantly higher in children from the high
exposure group (P,0.0001 versus both low and medium groups).
In contrast, the median anti-gSG6-P2 IgG level appeared closely
similar between the low and high groups of exposure (non-
significant), although a significant difference (P,0.05) was
observed when comparing medium and high groups. In addition,
the evolution of the specific IgG antibody response to gSG6-P1
and gSG6-P2 peptides in children (n=175) was evaluated between
the peak (September) and the end (December) of the exposure
season (data not shown). The specific IgG response was
significantly higher in December as compared to September only
for gSG6-P1 (P=0.0137, Wilcoxon matched pairs test). Altogeth-
er, these results showed that only the IgG response to gSG6-P1
increased with the level of exposure to An. gambiae, evaluated by
classical entomological data.
Figure 2. Amino-acid sequence of gSG6 Peptides. Amino-acid sequence of the SG6 protein of Anopheles gambiae (gi:13537666) is presented
and sequences of the selected peptides, gSG6-P1 to gSG6-P5, are underlined. Signal peptide (SP) sequence is indicating by dotted underline.
doi:10.1371/journal.pone.0002472.g002
Figure 3. IgG antibody response according to gSG6 peptides.
For each gSG6 peptide, the IgG antibody level was evaluated in a
subsample of children living in the studied area. Results at the peak of
the season of Anopheles exposure are reported according to gSG6
peptides. Results are presented by box plot graph where lines of the
boxes represent the 75th percentile, median and 25th percentile of
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In this present study, the Ab response specific to Anopheles
gambiae gSG6 salivary protein, from its recombinant form to
synthetic peptides, was investigated in children living in a malaria
endemic area in Senegal. We have shown for the first time that
exposed individuals develop an IgG response to gSG6 protein,
with considerable variations among children. With the objective of
optimizing Anopheles specificity and reproducibility of the immu-
nological assay, a peptide design approach was undertaken using
bioinformatic tools. Based on these analyses, five gSG6 peptides
were selected for their potential immunogenic properties and for
their presumed absence of cross-reactivity (on the basis of identity
and similarity) with proteins of other arthropod vectors or
pathogens/organisms whose genome or EST libraries are
available. The specific IgG level to gSG6 peptides was then
evaluated according to the level of exposure as estimated by
entomological data. The five gSG6 peptides were antigenic, but
the intensity of their specific IgG responses appeared peptide-
dependent. Indeed, gSG6-P1 and gSG6-P2 showed the highest
level of antigenicity in exposed children, whereas gSG6-P3, gSG6-
P4 and gSG6-P5 presented lower levels. This immuno-epidemi-
ological analysis confirmed bioinformatic predictions and enabled
us to identify gSG6-P1 and gSG6-P2 as high antigenic peptides.
However, only the IgG response to gSG6-P1 increased with the
degree of exposure to An. gambiae bites, as estimated by classical
entomological methods, and in agreement with previous observa-
tions of the IgG response to WSE in the same area [11]. Along
with the significant increase in anti-gSG6-P1 IgG during the rainy
season, these results indicated that the IgG Ab response to gSG6-
P1 was positively associated with the exposure to the An. gambiae
vector. Overall, this step-by-step original approach points to
gSG6-P1 as a potential candidate as an immuno-epidemiological
marker of exposure to An. gambiae bites.
The evaluation of immune responses to salivary components
might represent a means for assessing individual exposure to
vector bites. Previous studies on malaria vectors investigated the
Ab response to Anopheles WSE or to salivary gland extracts in
individuals living in malaria endemic areas. The specific IgG
response to Anopheles saliva appeared to be a potential indicator of
exposure to vector bites in Senegal [11] and Thailand [12].
Nevertheless, collection of saliva and/or salivary gland extracts is
tedious and time-consuming; in addition, saliva composition can
be affected by several ecological parameters such as age, feeding
status or infectivity of Anopheles [29], which in turn may influence
the anti-saliva immune response measured in exposed individuals.
A further complication lies in the widespread occurrence of some
families of salivary proteins in hematophagous arthropod species,
which may induce the presence of cross-reactive antibodies in
human sera [13]. An ideal alternative would be the availability of a
single immunogenic salivary protein specific to a given vector
species. This approach has been previously investigated by our
team for Glossina species, vectors of trypanosomatidae [30] and
recently for An. gambiae [31]. To define an immunological marker
of specific exposure to Anopheles genus, in terms of specificity,
sensitivity and reproducibility, we explored the composition in
salivary proteins of different insect vector species among
transcriptomic and genomic studies. The gSG6 salivary protein,
first described in An. gambiae [32], was further reported as being
specific to Anopheles mosquitoes and highly conserved among
Anopheles species [19,33]. Indeed, sequence alignment indicated
high identity: SG6 of An. gambiae shared 75% identity with An.
stephensi and 76% with An. funestus [34]. In addition, the An. gambiae
gSG6 protein has been reported to be potentially antigenic in
travelers exposed for short periods to Anopheles bites [20], and it
was confirmed as being antigenic in Senegalese children by an
immuno-proteomic approach coupling 2D immunoblot and mass
spectrometry (Cornelie S., unpublished data). In the present study,
we observed that the level of IgG to gSG6 protein was clearly
individual-dependent and may represent a tool to discriminate
exposure at the individual level. Altogether, these results indicated
the strong potential of gSG6 protein as a candidate marker of
exposure to Anopheles gambiae bites.
The peptide design strategy has strengthened the specificity of
markers to An. gambiae and in particular, we demonstrated that a
single peptide, gSG6-P1 could be the candidate as a marker of
exposure. Indeed, this peptide appeared to satisfy several
requirements that such an exposure marker should fulfill. First,
it thus far appears to be specific to the Anopheles genus and
therefore, no relevant cross-reactivity phenomena with epitopes
from other proteins (main Diptera species or pathogens) would be
expected. Nevertheless, few vector genomes are currently available
Figure 4. IgG response to gSG6-P1 and gSG6-P2 according to intensity of exposure to Anopheles gambiae bites. Individual DOD values
in September (peak of the season of Anopheles exposure) are shown for the three different exposure groups. Results are presented for the same
children (n=241) for gSG6-P1 (A) and gSG6-P2 (B). Exposure groups were defined by entomological data. Bars indicate median value for each
exposure group. Statistical significance between the 3 groups is indicated (non-parametric Mann-Whitney U-test).
doi:10.1371/journal.pone.0002472.g004
Biomarker An.gambiae Exposure
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among other major insect vectors. Second, because it is of a
synthetic nature, it guarantees high reproducibility of the
immunological assay. Third, it elicits a specific Ab response which
correlates well with the level of exposure to An. gambiae bites.
In the studied area, the main vector of Plasmodium falciparum has
been reported to be An. arabiensis [11,21], a species belonging to
the An. gambiae s.l. complex and whose genome is not currently
available. gSG6 peptides were designed on the basis of the An.
gambiae s.s. sequence, the only Anopheles genome available [35],
which may perhaps result in an under-estimation of the immune
response in the studied children, as previously mentioned [11].
Nevertheless, gSG6-P1 shares 82% and 91% identity with An.
stephensi and An. funestus, respectively, two species with greater
evolutionary distance from An. gambiae s.s. as compared to An.
arabiensis. The above observation tends to support the notion that
gSG6-P1 can be used to evaluate the exposure to other Anopheles
vectors of malaria. Obviously, confirmation in other transmission
areas presenting different malaria transmission modalities is
needed. In addition to the applications already mentioned, there
exist a number of other useful applications of a marker of exposure
to Anopheles bites. It will be interest to evaluate gSG6 peptides in
areas with different modalities of transmission, both in term of
intensity and of the dynamics of exposure. For example, it would
be very useful to identify low exposure, for which entomological
studies are not sensitive enough (dry season, malaria according to
altitude, urban exposure) or adequate (travelers, military corps).
One direct application of such a gSG6 peptide marker of
exposure could lie in the elaboration of maps representing the risk
of exposure to Anopheles bites. The development of such immuno-
epidemiological markers might represent a quantitative tool
applied to field conditions and a complementary tool to those
currently available, such as entomological, ecological and
environmental data [36]. It could represent a geographic indicator
of the risks of malaria transmission and thus a useful tool for
predicting malaria morbidity risk as previously described [5].
Furthermore, it may represent a powerful tool for evaluation of
vector control strategies (impregnated bednet, intradomiciliary
aspersion, etc.) and could here constitute a direct criterion for
effectiveness and appropriate use (malaria control program).
In conclusion, we have developed an original approach
coupling bioinformatic and immuno-epidemiological tools, which
succeeded in identifying a candidate for developing a marker of
exposure to An. gambiae bites. A similar methodology could be
applied to the challenge inherent in control of other vector-borne
diseases.
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